Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214034 | 0.87 | NPC1 (0.41) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7214714 | 0.87 | NPC1 (0.41) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7214057 | 0.87 | NPC1 (0.41) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7214420 | 0.86 | HDAC1 (0.32) | HDAC1HDAC6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7220424 | 0.86 | NPC1 (0.41) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7510265 | 0.85 | SIGMAR1 (0.42) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7214121 | 0.84 | NPC1 (0.34) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7220913 | 0.84 | HTT (0.38) | HDAC1HDAC6SIGMAR1NPC1 | |
| SCHEMBL7213843 | 0.82 | NPC1 (0.33) | HDAC1HDAC6SIGMAR1NPC1 | |
| Hydrochloric Acid SCHEMBL7216056 | 0.82 | KDM1A (0.33) | HDAC1HDAC6SIGMAR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534499-B2 | For therapy of autoimmune disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | claimed |
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | US | claimed |
| EP-1172359-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | claimed |
| US-6534499-B2 | For therapy of autoimmune disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | US | disclosed |
| EP-1172359-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | TNF, NFKBIA, CHUK | HDAC1 2415/4885HDAC6 1605/4885SIGMAR1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.